

Wednesday 28. August	Room 2	Room 3	Room 4
	<p>Predictive Pharmacogenetics Prof Jules Desmeules/ Prof Ingolf Cascorbi</p>	<p>How to become a self-empowered patient Dr Christine Cedraschi/ Prof Donald Singer</p>	<p>Updates in clinical toxicology Dr Hugo Kupferschmidt/ Prof Gerald Rongen</p>
09.00 h	Genetics of treatment response in depression Antonio Drago	Collection and impact of patient reported outcomes Anne Viola	Lipid emulsion as a new antidote - current use, extension from lipophilic local anesthetics to other drugs, and state of the art Theodore C. Bania
09.30 h	Pharmacogenetics and other factors in individualization of oral anti-vitamine k anti-coagulants Philippe Beaune	Medication use: from leaflet to e-learning Valérie Piguet	Challenges in paracetamol poisoning Nicholas Bateman
10.00h	A promising predictor for heart diseases and diuretic drug therapy in the aldosterone receptor gene Nawar Dalila	How to govern a self-powered patient: privacy and biopower Sami Coll	New insights into the mechanisms of dioxin toxicity in humans Jean-Hilaire Saurat
10.15h	CYP2R1 genetic polymorphisms are associated with lower 25-hydroxy vitamin D levels in Lebanese subjects Nathalie Zgheib		
10.30h	coffee break		
	<p>Clinical trials methodologies Prof Thierry Buclin / Dr Ylva Böttiger</p>	<p>Special populations: prenatal pharmacology Dr Victoria Rollason / Prof Gerard Rongen</p>	<p>Networking in Clinical Toxicology Dr Hugo Kupferschmidt/ Prof Gonzalo Calvo</p>
11.00 h	Towards best reporting practices for clinical pharmacology trials Doug Altman	TINN (Treat Infections In Neonates) : an FP7 project Evelyne Jacqz-Aigrain	The poisons centres networks - toxicosurveillance Herbet Desel
11.30 h	The future of modeling and simulation approaches in drug development Marc Pfister	Studying teratogenic effects of medication use during pregnancy: challenges and pitfalls Marleen van Gelder	Networking for regulatory toxicology Martin Wilks
12.00h	Biases on the administered parenteral doses of an experimental drug during phase I clinical trials Nicolas Widmer	Pregnancy outcome following maternal exposure to mirtazapine: preliminary results of a collaborative entis study Ursula Winterfeld	The Swiss model of comprehensive antidote provision Hugo Kupferschmidt
12.15h	Critical review of the validation process of six predictive biomarkers: how good is the quality and quantity of the evidence? Joaquin Saez Penataro	Fetal exposure to nonsteroidal antiinflammatory drugs and spontaneous abortions Sharon Daniel	
12.30h	Lunch poster tour		

	Health therapies assessment	Dr Francois Girardin / Prof David Webb	Training tomorrow's prescribers	Prof Maxwell/ Prof Theo De Vries	The use of molecular imaging biomarkers in drug development (EANM)	Pr Halldin / Pr Adam Vas
13.30 h	The role of the clinical pharmacologist in pharmacoconomics /health economics	Michael Rawlins	The relevance of clinical workplace learning and assessment in CP&T	Tim Dornan	Translational PET in Neuroscience and Drug Development	Christer Halldin
14.00 h	The Scottish model: Scottish Medicines Consortium (SMC)	David Webb	A systematic follow-up of student-prescribers (track): therapeutic knowledge, skills/competencies and attitude	David Brinkman	The academia's view on collaboration with industry	Antony Gee
14.30h	An assessment of the accuracy of horizon scanning predictions of medicine use in the scottish national health service	Sharon Hems	Assessment of clinical pharmacology skills as part of the new integrated final exam for medical students at Karolinska Institutet	Marie-Louise Ovesjo	Opportunities and challenges of molecular imaging collaboration in pharmaceutical development	Paul Maguire
14.45h	Dabigatran - demonstrates the need for comprehensive approaches to optimise the use of new drugs	Brian Godman	The effect of a structured medical record on the recording of therapeutic information and communication between doctors	Robert Van Unen	Interaction between industry and academia: Developing PET imaging tracer for Novel Targets	Gilles Tamagnan
15.00h	coffee break					
	Health issues and communication	Pr Pierre Dayer/ Prof Donald Singer	Assessing and supporting tomorrow's prescribers (BPS)	Prof David Webb/ Prof Phil Routledge	Health economic assessment	Dr Francois Girardin/ Prof Michael Rawlins
15.30 h	Mediator (Benfluorex), a French and worldwide public health disaster	Irène Frachon	Development of a UK national Prescribing Skills Assessment	Simon Maxwell	The economics of personalised medicine and pharmacogenetic testing	Dyfrig Hughes
16.00 h	Risk perception among healthcare professionals and the public: experience from regional medicines information and pharmacovigilance centres in Norway	Jan Schjott	Undergraduate training for medical students in CPT and prescribing	Sarah Ross	Value Based Pricing to ensure cost effective drugs for the UK NHS: will it work?	Mark Sculpher
16.30h	The risk-benefit relationship as a moral compass	Michel Lievre	Electronic solutions to safer hospital prescribing	Jamie Coleman	Patented drug extension strategies on healthcare spending: a cost-evaluation analysis	Nathalie Vernaz
16.45h			Developing a standardised prescription chart to reduce error	Phil Routledge	Pharmacoeconomic drivers in pharmacogenomics	Stijn Vandekerckhove

17.00h	coffee break				
17.30h		Whats new in malaria therapeutics	Dr Andrea Bosman	Current trends in Global Pharmacovigilance (WHO)	Dr Lembit Rāgo
18.00h		Update on the status of artemisinin resistance	Pascale Ringwald	Safety information today and how can we improve tomorrow?	Andrzej Czarnecki
18.30h	Plenary 1: Innate immune sensing of nucleic acids and application for oligonucleotide-based immunotherapy	Prof Günter Hartmann			
19h15	Opening ceremony				
20h15	Welcome reception				

Thursday 29. August 2013		Room 2	Room 3	Room 4
		Personalizing cancer therapy (ASCPT) Dr Caroline Samer/ Prof Matthias Schwab	New developments in TDM Prof Thierry Buclin/ Dr Ylva Böttiger	Pharmacovigilance networks (WHO) Dr Lembit Rägo/ Dr Shanthi Pal
09.00h	The individualisation of cancer therapy in organ dysfunction	Michelle Rudek	Monitoring drug therapy: TDM-te deum or tedium? Jeffrey Aronson	ENCEPP: Strengthening methodology, transparency and independence Henry Fitt
09.30h	Targeted therapies in hematological malignancies	Raymond Hohl	Strategies for the development of TDM for targeted anticancer agents Thierry Buclin	WHO Programme for International Drug Monitoring Shanthi Pal
10.00h	Personalized therapy in breast cancer	Matthias Schwab	A simplified method for busulfan therapeutic drug monitoring using dried blood spot sampling in pediatric patient undergoing stem cell transplantation Chakradhara Rao Uppugunduri	What is the additional value of electronic medical records for drug safety signal detection? The experience of EU-ADR project Gianluca Trifiro
10.15h			Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from the randomized controlled i-come trial Verena Gotta	
10.30h	coffee break			
11.00h	Plenary 2:Anti-Angiogenic Therapy: New Insights	Prof Napoleone Ferrara		
11.45h	EACPT scientific and special Awards			
12.00h	Lunch poster tour		Innovative medicine initiative Dr Elisabetta Vaudano / Prof Adam Vas	Lunch poster tour
12.15h			IMI: A Public Private Partnership approach to the boosting of pharmaceutical R&D Elisabetta Vaudano	
12.40h			Creating new models for R&D in areas of unmet clinical need: Autism Spectrum Disorder Will Spooren , Roche	
13.05h			Addressing the challenges of diabetes and its complication: The IMI Diabetes Platform Bernd Jablonka, Sanofi	
			A PPP approach to boost antimicrobial resistance R&D: the ND4BB IMI platform Seamus O'Brien, Astra Zeneca	

	Clinical trials regulation, control, benefits	Dr Emilie Alirol/ Prof Gonzalo Calvo	Inflammatory disease and Biotherapeutics	Dr Francois Curtin / Prof Edoardo Spina	Drug Safety: from clinical trials to clinical practice (WHO)	Dr Lembit Rägo/ Dr Shanthi Pal
13.30 h	Introductory remarks to the revision of the EU Clinical Trials regulation	Gonzalo Calvo	New targets in the treatment of rheumatoid arthritis	Zoltán Szekanecz	CIOMS-From clinical trials to clinical practice-recent development	Gunilla Sjölin-Forsberg
14.00 h	The clinical researcher view: Ideas for improvement	Cristina Avendaño	Multiple Sclerosis - New chances ?	François Curtin	The New Zealand centre for adverse drug reactions monitoring: a source of practice-based evidence	Ruth Savage
14.30h	Clinical and non-interventional trials assessment in Croatia	Dinko Vitezic	Up-titration study with ponesimod, a selective s1p1 receptor modulator, to assess its maximum tolerated dose in healthy subjects	Matthias Hoch	Regulatory decisions and drug safety – views from an agency outside EU	Rudolf Stoller
14.45h	The number of included older people in recent pre-authorization trials	Erna Beers	Off-label use and adverse events of biologic agents in paediatric patients with juvenile idiopathic arthritis	Julie Broe		
15.00h	coffee break					
	Frontiers in Pharmacology (BPS)	Prof Mounir Pirmohamed/ Pr Mark Caulfield	Ocular Pharmacology	Dr Edoardo Baglivo/ Prof Zoltan Szekanecz	Drug Safety in emerging countries (WHO)	Dr Lembit Rägo/ Dr Shanthi Pal
15.30 h	Novel clinical trial designs for assessing the efficacy of drugs	Max Parmar	Anti-TNF in ocular diseases	Ildiko Süveges	Drug safety in emerging countries - a perspective from Nigeria	Ambrose Isah
16.00 h	Novel mechanistic biomarkers of drug-induced liver injury	Kevin Park	Non infectious intermediate and posterior uveitis: treatment and place of local corticosteroids	Massimo Accorinti	Latin-American Pharmacovigilance update report: a quick overview	Mariano Madurga Sanz
16.30h	Advances in genomics of blood pressure - time for translation	Mark Caulfield	Interferon alpha and posterior uveitis	Christine Fardeau	Overview of pharmacovigilance in resource limited settings: challenges and opportunities	Sten Olsson
16.45h			Sjögren ocular disease treatment	László Modis		
17.00h	coffee break					
	Pharmacology of Chocolate	Prof Jules Desmeules	The dopamine D3 receptor as a potential target for psychiatric diseases (sponsored by Gideon Richter)	Dr Gerhard Gründer / Prof Adam Vas		
17.30h	Chocolate: pleasure for health	Claude Pichard	Antagonists and partial agonists at D2 and D3 dopamine receptors in psychiatric disorders: the spectrum of therapeutic options	Gerhard Gründer		
18.00h	Chocolate: pleasure for health	Jeremy Ramsauer	The functional role of D2 versus D3 dopamine receptors in health and disease	Peter Gmeiner		
18.30h			Imaging the dopamine D2 and dopamine D3 receptors in the living brain	Ilan Rabiner		
			A D3/D2 partial agonist antipsychotic with preferential D3 binding on the horizon	István Laszlovszky		
			Concluding remarks	Gerhard Gründer		
19.00h	Chocolate tasting and cultural event					

Friday 30. August 2013	Room 2	Room 3	Room 4
	Diabetes Dr Markus Hodel / Prof Matthias Schwab	PK/PD modelling Prof Chantal Csajka / Prof Kim Broesen	Who should initiate drug development ? Prof Oliver Hartley / Prof Adam Vas
09.00h	Novel antidiabetics: should they be used at all - and in whom? Christoph Meier	The role of modelling and simulation in clinical pharmacology Kayode Ogungbenro	Industry is more fit for clinical trials than academy Adam Vas
09.30h	Diabetes, diabetes risk factors and treatments, and breast cancer Peter Boyle	Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1 using the population approach Charlotte Kloft	Academia isn't so bad either Nicholas Moore
10.00h	Do treatment quality indicators predict cardiovascular outcomes in patients with diabetes? Grigory Sidorenko	Intrapulmonary pharmacokinetics and the intracellular disposition to support the long-lasting efficacy after an inhaled administration of its prodrug laninamivir octanoate Kaoru Toyama	Clinical trials registry and good clinical practice: an indian scenario Bikash Medhi
10.15h	Addressing the challenges of diabetes and its complication: the IMI diabetes platform Bernd Jablonka	Optimal sampling strategy for busulfan in stem cell transplantation patients Francine Castro	Interchangeability of gabapentin generic formulations in the netherlands: a comparative bioavailability study Marc Maliepaard
10.30h	coffee break		
11.00h	Plenary 3: Immune mechanisms of atherosclerosis Prof Ziad Mallat		
11.45h	EACPT Lifetime Achievement Awards		

12.00h							Lunch poster tour						
Special cardiovascular pharmacology			Prof Jean-Luc Reny / Prof Tabassome Simon		Ethics		Prof P Ducor/ Prof Ingolf Cascorbi		Special liver pharmacology			Prof Gerd Kullak / Prof Kari Kivisto	
13.30 h	Clinical drug developpement of new anticoagulants : a lesson of modern clinical pharmacology		Patrick Mismetti		Ethics and Privacy of Biobanks		Berenice Elger		Immunological aspects of drug hypersensitivity – from molecule to man			Kevin Park	
14.00 h	Novel approaches in the treatment of dyslipidemias		Anton F Stalenhoef		Public health genomics and personalized healthcare		Angela Brand		Acetaminophen-induced liver injury in experimental animals and humans			Hartmut Jaeschke	
14.30h	Reversal strategy in antagonizing the P2Y12-inhibitor ticagrelor		Eva-Luise Hobl						Assessment of drug-induced liver injury from clinical trial data			Michael Merz	
14.45h	Impact of circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction		Tabassome Simon										
15.00h							coffee break						
Drug-drug Interactions			Dr Youssef Daali / Prof Kim Broesen		Advances in the treatment of rare diseases. Expectations on advanced therapies		Dr Ilse Kern / Prof Gonzalo Calvo		New targets for pain treatment			Prof Jules Desmeules/ Prof Dinko Vitezic	
15.30 h	Complexity of predicting the magnitude of drug-drug interactions in an individual patient: this cannot fit to a pocket guide; ipad may be!		Amin Rostami-Hodjegan		New developments in the treatment of Inborn Errors of Metabolism		Matthias Baumgartner		Targets for drug development in HIV neuropathy			Andrew Rice	
16.00 h	Role of membrane transporters in drug interactions		Mikko Niemi		Treating rare inborn errors of metabolism : from theory to practice		Matthias Gautschi		Transient receptor potential channels as novel drug targets			Pierangelo Geppetti	
16.30h	Interaction between mycophenolate mophetil and tacrolimus in kidney graft recipients		Jan Strojil		Gene therapy approval process at EMA		Sol Ruiz		Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized double-blind placebo-controlled trial			Alain Matthey	
16.45h	Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite in healthy volunteers		Anne M Filppula						A new pharmaceutical form of paracetamol : efficacy of transmucous buccal paracetamol in acute pain patients			Gisele Pickering	

17.00h	coffee break			
	Future Challenges for Clinical Pharmacology in Health Care	Prof Folke Sjöqvist / Lembit Rägo	Methodological issues in clinical trials with CNS drugs (Italian Society)	Prof Pier Luigi Canonico/ Prof Edoardo Spina
17.30h	The background to the new WHO/IUPHAR/CIOMS manifesto entitled "Clinical Pharmacology in Health Care, Teaching and Research" and the importance of the focus on health care.	Folke Sjöqvist	Clinical trials in epilepsy	Emilio Perucca
18.00h	Historical development and current state of Clinical Pharmacology in Russia	Ksenia Zagorodnikova	Clinical trials in neuropathic pain	Soren Sindrup
18.30h	Clinical Pharmacology in Healthcare in Croatia	Vera Vlahovic-Palcevsk	Clinical trials in schizophrenia	Wolfgang Fleischacker
	Gala dinner			

Saturday 31. August 2013	Room 2	Room 3	Room 4
9.00h	<p>Best abstract, oral communications Prof Pierre Dayer / Prof Gonzalo Calvo</p> <p>Generic substitution of antiepileptic drug (AED) and loss of seizure control: a population-based case-crossover study Elisabeth Polard</p> <p>Parenteral Busulfan in Myeloablative conditioning regimens for hematopoietic stem-cell transplantation (HSCT) in children Daniela Janeckova</p> <p>Cedia assays for buprenorphine, methadone and EDDP in urine – simple methods, but sufficient for the purpose? Jon Berg</p> <p>Target gene evaluation of two mirnas differently expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients Sierk Haenisch</p> <p>Self-empowering patients – a promising example in oral anticoagulation Stefan Vormfelde</p> <p>Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment Victoria Rollason</p>	<p>Doping: Sports and Pharmacologists Dr Mitsuko Kondo / Dr Martial Saugy</p> <p>Development of partnerships between the biopharmaceutical industry and the world anti-doping agency Olivier Rabin</p> <p>Doping in sport: The biomarkers are the best tools to measure its prevalence and to establish the individual monitoring of the athletes Martial Saugy</p> <p>The makings of the world-class athlete: physiologic, genetic, psychosocial and economic determinants Yannis Pitsiladis</p>	<p>Neuro-Psychopharmacology: filling the gaps Dr Marie Besson / Prof Edoardo Spina</p> <p>Prediction of pharmacological effects of CNS-active agents during early phases of drug development Joop Van Gerven</p> <p>New strategies in the treatment of major depression Francesc Artigas</p> <p>Sleep quality of chronic benzodiazepine users in nursing homes: a comparative study with non-users. Jolyce Bourgeois</p> <p>Indications and dosages of atypical antipsychotics in Belgian nursing homes Majda Azermai</p>
10.30h	Coffee poster tour		
11.15h	Closing ceremony and poster awards		
12.00h			